A patient is eligible for an experimental treatment if the patient has:
- (1) evaluated other treatment options currently approved by the United States food and drug administration;
- (2) received a recommendation from the patient's treating health care provider for an experimental treatment;
- (3) given informed consent for the use of the experimental treatment; and
- (4) received documentation from the treating health care provider that the patient meets the requirements of this section.
History: En. Sec. 4, Ch. 135, L. 2015; amd. Sec. 3, Ch. 413, L. 2023; amd. Sec. 8, Ch. 621, L. 2025.